Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

3-Needle vs 5-Needle of Genicular Nerve Block on Pain and Quality of Life in Knee Osteoarthritis

NCT07853170 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-10-04
Last updated
2026-10-06

Condition(s) studied

3-Needle5-NeedleGenicular Nerve BlockPainQuality of LifeKnee Osteoarthritis

Investigational drug(s) / intervention(s)

3-nerve-targeted group5-nerve-targeted group

3-nerve-targeted group: Patients will receive 3-nerve protocol.

5-nerve-targeted group: Patients will receive 5-nerve protocol.

Study summary

This study aims to compare the 3-needle and 5-needle of genicular nerve block on pain and quality of life in Knee osteoarthritis (KOA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years. * Both sexes. * Patients with unilateral chronic knee pain for more than 3 months. * Patients received conservative treatment for at least 3 months. * Diagnosed Knee osteoarthritis (KOA) according to the American College of Rheumatology (ACR) criteria, and grade greater than or equal to Kellgren-Lawrence grade 2. Exclusion Criteria: * Chronic knee pain is due to causes other than KOA, such as connective tissue diseases, lumbar radicular neuropathy (spondylolisthesis, spinal stenosis), or sciatic pain. * Knee effusion. * Neuro/psychiatric disorders. * History of intra-articular injection in the prior 3 months. * Prior knee surgery. * Active systemic or local knee infections; anticoagulant use.

Primary outcome measure(s)

  • Degree of pain — 6 months postoperatively
    Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta El-Gharbia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07853170 on ClinicalTrials.gov ↗ ← All trials in Egypt